{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:27:44Z","timestamp":1793734064195,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8041","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.1038\/s41586-024-08137-x","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:01:59Z","timestamp":1730293319000},"page":"241-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax"],"prefix":"10.1038","volume":"636","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8763-4270","authenticated-orcid":false,"given":"Junya","family":"Sango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-1045","authenticated-orcid":false,"given":"Saul","family":"Carcamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-8071","authenticated-orcid":false,"given":"Maria","family":"Sirenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hager","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulay","family":"Ulukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-7138","authenticated-orcid":false,"given":"Lewis E.","family":"Tomalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Cruz-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Olszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9288-1746","authenticated-orcid":false,"given":"Emmanuel","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Jaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-8425","authenticated-orcid":false,"given":"Bettina","family":"Nadorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5675-9102","authenticated-orcid":false,"given":"Benjamin","family":"Kroger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-7594","authenticated-orcid":false,"given":"Feng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0709-2759","authenticated-orcid":false,"given":"Elvin","family":"Wagenblast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-3291","authenticated-orcid":false,"given":"Ronan","family":"Chaligne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6442-1419","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-0407","authenticated-orcid":false,"given":"Deniz","family":"Demircioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan A.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2196-3503","authenticated-orcid":false,"given":"Piro","family":"Lito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-8983","authenticated-orcid":false,"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7002-417X","authenticated-orcid":false,"given":"Eirini P.","family":"Papapetrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"8137_CR1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"8137_CR2","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616\u20133627 (2013).","journal-title":"Blood"},{"key":"8137_CR3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles, L. A. et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature 587, 477\u2013482 (2020).","journal-title":"Nature"},{"key":"8137_CR4","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita, K. et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat. Commun. 11, 5327 (2020).","journal-title":"Nat. Commun."},{"key":"8137_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2643-3230.BCD-21-0155","volume":"3","author":"AJ Menssen","year":"2022","unstructured":"Menssen, A. J. et al. Convergent clonal evolution of signaling gene mutations is a hallmark of myelodysplastic syndrome progression. Blood Cancer Discov. 3, 330\u2013345 (2022).","journal-title":"Blood Cancer Discov."},{"key":"8137_CR6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","volume":"49","author":"H Makishima","year":"2017","unstructured":"Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204\u2013212 (2017).","journal-title":"Nat. Genet."},{"key":"8137_CR7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ccell.2018.11.009","volume":"35","author":"AJ Levine","year":"2019","unstructured":"Levine, A. J., Jenkins, N. A. & Copeland, N. G. The roles of initiating truncal mutations in human cancers: the order of mutations and tumor cell type matters. Cancer Cell 35, 10\u201315 (2019).","journal-title":"Cancer Cell"},{"key":"8137_CR8","doi-asserted-by":"crossref","first-page":"a027060","DOI":"10.1101\/cshperspect.a027060","volume":"7","author":"DG Kent","year":"2017","unstructured":"Kent, D. G. & Green, A. R. Order matters: the order of somatic mutations influences cancer evolution. Cold Spring Harb. Perspect. Med. 7, a027060 (2017).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"8137_CR9","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"8137_CR10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648 (1994).","journal-title":"Nature"},{"key":"8137_CR11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"8137_CR12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett, J. M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33, 451\u2013458 (1976).","journal-title":"Br. J. Haematol."},{"key":"8137_CR13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104\u2013108 (2017).","journal-title":"Nature"},{"key":"8137_CR14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212\u20131223 (2022).","journal-title":"Nat. Med."},{"key":"8137_CR15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"8137_CR16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva, M. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 6, 1106\u20131117 (2016).","journal-title":"Cancer Discov."},{"key":"8137_CR17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med."},{"key":"8137_CR18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"8137_CR19","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 7, e724\u2013e736 (2020).","journal-title":"Lancet Haematol."},{"key":"8137_CR20","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A. H. et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145 (2020).","journal-title":"Blood"},{"key":"8137_CR21","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia, T. M. et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 40, 3848\u20133857 (2022).","journal-title":"J. Clin. Oncol."},{"key":"8137_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"8137_CR23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanmaki","year":"2020","unstructured":"Kuusanmaki, H. et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105, 708\u2013720 (2020).","journal-title":"Haematologica"},{"key":"8137_CR24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat. Cancer 1, 826\u2013839 (2020).","journal-title":"Nat. Cancer"},{"key":"8137_CR25","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl, M. et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 5, 1552\u20131564 (2021).","journal-title":"Blood Adv."},{"key":"8137_CR26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek, A. et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov. 13, 1408\u20131427 (2023).","journal-title":"Cancer Discov."},{"key":"8137_CR27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","volume":"28","author":"T Wang","year":"2021","unstructured":"Wang, T. et al. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell 28, 1074\u20131089 e1077 (2021).","journal-title":"Cell Stem Cell"},{"key":"8137_CR28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.stem.2017.01.009","volume":"20","author":"AG Kotini","year":"2017","unstructured":"Kotini, A. G. et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell 20, 315\u2013328 e317 (2017).","journal-title":"Cell Stem Cell"},{"key":"8137_CR29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/ng.3646","volume":"48","author":"MR Corces","year":"2016","unstructured":"Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193\u20131203 (2016).","journal-title":"Nat. Genet."},{"key":"8137_CR30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-22-0167","volume":"4","author":"AG Kotini","year":"2023","unstructured":"Kotini, A. G. et al. Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia. Blood Cancer Discov. 4, 318\u2013335 (2023).","journal-title":"Blood Cancer Discov."},{"key":"8137_CR31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-019-1367-0","volume":"571","author":"AS Nam","year":"2019","unstructured":"Nam, A. S. et al. Somatic mutations and cell identity linked by genotyping of transcriptomes. Nature 571, 355\u2013360 (2019).","journal-title":"Nature"},{"key":"8137_CR32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/ncb3493","volume":"19","author":"L Velten","year":"2017","unstructured":"Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271\u2013281 (2017).","journal-title":"Nat. Cell Biol."},{"key":"8137_CR33","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer 4, 27\u201342 (2023).","journal-title":"Nat Cancer"},{"key":"8137_CR34","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard, E. et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 1, EVIDoa2200008 (2022).","journal-title":"NEJM Evid."},{"key":"8137_CR35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21219","volume":"92","author":"S Matarraz","year":"2017","unstructured":"Matarraz, S. et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytometry B Clin. Cytom. 92, 218\u2013227 (2017).","journal-title":"Cytometry B Clin. Cytom."},{"key":"8137_CR36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nbt.3178","volume":"33","author":"AG Kotini","year":"2015","unstructured":"Kotini, A. G. et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat. Biotechnol. 33, 646\u2013655 (2015).","journal-title":"Nat. Biotechnol."},{"key":"8137_CR37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt, S. et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell 38, 872\u2013890 e876 (2020).","journal-title":"Cancer Cell"},{"key":"8137_CR38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan, R. et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 4, 362\u2013375 (2014).","journal-title":"Cancer Discov."},{"key":"8137_CR39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti, A. et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106, 894\u2013898 (2021).","journal-title":"Haematologica"},{"key":"8137_CR40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","volume":"381","author":"CJ Schulze","year":"2023","unstructured":"Schulze, C. J. et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science 381, 794\u2013799 (2023).","journal-title":"Science"},{"key":"8137_CR41","doi-asserted-by":"crossref","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","DOI":"10.1038\/s41586-024-07205-6"},{"key":"8137_CR42","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2005-06-2325","volume":"107","author":"DJ Pearce","year":"2006","unstructured":"Pearce, D. J. et al. AML engraftment in the NOD\/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107, 1166\u20131173 (2006).","journal-title":"Blood"},{"key":"8137_CR43","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086\u20131093 (2011).","journal-title":"Nat. Med."},{"key":"8137_CR44","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 13, 2032\u20132049 (2023).","journal-title":"Cancer Discov."},{"key":"8137_CR45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct. Target Ther. 7, 51 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"8137_CR46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/1535-7163.MCT-21-0690","volume":"21","author":"BZ Carter","year":"2022","unstructured":"Carter, B. Z. et al. Maximal activation of apoptosis signaling by cotargeting antiapoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol. Cancer Ther. 21, 879\u2013889 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"8137_CR47","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel, S. et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 8, 1582\u20131597 (2018).","journal-title":"Cancer Discov."},{"key":"8137_CR48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275\u2013291 (2014).","journal-title":"Cell Stem Cell"},{"key":"8137_CR49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","volume":"15","author":"JC Wang","year":"2005","unstructured":"Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494\u2013501 (2005).","journal-title":"Trends Cell Biol."},{"key":"8137_CR50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/13793","volume":"23","author":"WJ Song","year":"1999","unstructured":"Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166\u2013175 (1999).","journal-title":"Nat. Genet."},{"key":"8137_CR51","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/bloodadvances.2020002709","volume":"5","author":"MC Krutein","year":"2021","unstructured":"Krutein, M. C. et al. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Adv. 5, 687\u2013699 (2021).","journal-title":"Blood Adv."},{"key":"8137_CR52","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.stemcr.2018.03.020","volume":"10","author":"CJ Chang","year":"2018","unstructured":"Chang, C. J. et al. Dissecting the contributions of cooperating gene mutations to cancer phenotypes and drug responses with patient-derived iPSCs. Stem Cell Rep. 10, 1610\u20131624 (2018).","journal-title":"Stem Cell Rep."},{"key":"8137_CR53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.stem.2014.05.018","volume":"15","author":"F Gonzalez","year":"2014","unstructured":"Gonzalez, F. et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell 15, 215\u2013226 (2014).","journal-title":"Cell Stem Cell"},{"key":"8137_CR54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"8137_CR55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/bioinformatics\/btv715","volume":"32","author":"P Angerer","year":"2016","unstructured":"Angerer, P. et al. destiny: diffusion maps for large-scale single-cell data in R. Bioinformatics 32, 1241\u20131243 (2016).","journal-title":"Bioinformatics"},{"key":"8137_CR56","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"8137_CR57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10802-z","volume":"10","author":"D Tsoucas","year":"2019","unstructured":"Tsoucas, D. et al. Accurate estimation of cell-type composition from gene expression data. Nat. Commun. 10, 2975 (2019).","journal-title":"Nat. Commun."},{"key":"8137_CR58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"8137_CR59","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cll.2017.07.004","volume":"37","author":"J Xu","year":"2017","unstructured":"Xu, J., Jorgensen, J. L. & Wang, S. A. How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia? Clin. Lab. Med. 37, 787\u2013802 (2017).","journal-title":"Clin. Lab. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08137-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08137-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:07:50Z","timestamp":1733310470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-08137-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":59,"journal-issue":{"issue":"8041","published-print":{"date-parts":[[2024,12,5]]}},"alternative-id":["8137"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-08137-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. receives research support from Klondike, AbbVie\u00a0and Janssen, and consulting fees from AbbVie,\u00a0Syndax, Novartis, Servier, AbbVie, Menarini-Stemline Therapeutics, Adaptive, Dark Blue Therapeutics, MEI Pharma, Legend Biotech, Sanofi Aventis, Auxenion GmbH, Vincerx, Curis, Intellisphere and\u00a0Janssen. D.A.L. is an advisory board member of Mission Bio, Veracyte, Pangea and Alethiomics and has received research support from Ultima Genomics unrelated to this work. A.M. receives research support from Chimeric Therapeutics, Lin Biosciences, Hibercell Inc., Qurient and Molecular Templates, Inc. C.D.D. has received consulting fees from Abbvie, AstraZeneca, Astellas, GenMab, Notable Labs, Rigel and Servier. E.P. is cofounder of, and holds a fiduciary role in Isabl Inc.\u00a0P.L. has received grants to his Institution from Amgen, Mirati, Revolution Medicines, Boehringer Ingelheim and Virtec Pharmaceuticals. P.L. is an advisory board member of Frontier Medicines, Ikena, Biotheryx and PAQ-Tx (consulting fees and equity in each) and has received consulting fees or honoraria from Black Diamond Therapeutics, AmMax, OrbiMed, PAQ-Tx, Repare Therapeutics, Boehringer Ingelheim and Revolution Medicines. EPP has received consulting fees or honoraria from Janssen, Daiichi Sankyo and Cellarity, unrelated to the current study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}